Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer

Kimiko Ferguson; Arti Yadav; Susan Morey; Julia Abdullah; Gabriel Hrysenko; Jing Ying Eng; Munawwar Sajjad; Stephen Koury; Kate Rittenhouse-Olson

doi:10.2217/fon.13.209

Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer

Kimiko Ferguson
, Arti Yadav
, Susan Morey
, Julia Abdullah
, Gabriel Hrysenko
, Jing Ying Eng
, Munawwar Sajjad
, Stephen Koury
, Kate Rittenhouse-Olson

SUNY Buffalo

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Aim: The Thomsen-Friedenreich antigen (TF-Ag) is a disaccharide hidden on normal cells, but selectively exposed on the surface of breast, colon, prostate and bladder cancer cells. JAA-F11, a highly specific monoclonal antibody to TF-Ag, reduces metastasis and prolongs survival in a mouse model. In addition, ¹²⁴I-JAA-F11 localizes 4T1 tumors in mice. These studies continue translation of JAA-F11 to human breast cancer. Materials & methods & results: Of the 41 human breast cancer cell lines tested, 78% were positive for reactivity with JAA-F11 by whole-cell enzyme immunoassay and positivity occurred unrelated to estrogen, progesterone or HER2 receptor status. JAA-F11 inhibited the growth rate of the human cancer cell lines tested. At 1 h, approximately 80% of JAA-F11 internalized in the three cell lines tested. ¹²⁴I-JAA-F11 specifically imaged human triple-negative tumors in mice by microPET. Conclusion: The results highlight the potential that humanized JAA-F11 may have for immunotherapy and drug conjugate therapy in breast cancer patients.

Original language	English
Pages (from-to)	385-399
Number of pages	15
Journal	Future Oncology
Volume	10
Issue number	3
DOIs	https://doi.org/10.2217/fon.13.209
State	Published - Feb 2014

Keywords

Enzyme immunoassay
Human breast cancer cell lines
JAA-F11 monoclonal antibody
Monoclonal antibody
Thomsen-Friedenreich antigen

Access to Document

10.2217/fon.13.209

Cite this

@article{97d9ad5274a7431bb383b311577efb8c,

title = "Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer",

abstract = "Aim: The Thomsen-Friedenreich antigen (TF-Ag) is a disaccharide hidden on normal cells, but selectively exposed on the surface of breast, colon, prostate and bladder cancer cells. JAA-F11, a highly specific monoclonal antibody to TF-Ag, reduces metastasis and prolongs survival in a mouse model. In addition, 124I-JAA-F11 localizes 4T1 tumors in mice. These studies continue translation of JAA-F11 to human breast cancer. Materials \& methods \& results: Of the 41 human breast cancer cell lines tested, 78\% were positive for reactivity with JAA-F11 by whole-cell enzyme immunoassay and positivity occurred unrelated to estrogen, progesterone or HER2 receptor status. JAA-F11 inhibited the growth rate of the human cancer cell lines tested. At 1 h, approximately 80\% of JAA-F11 internalized in the three cell lines tested. 124I-JAA-F11 specifically imaged human triple-negative tumors in mice by microPET. Conclusion: The results highlight the potential that humanized JAA-F11 may have for immunotherapy and drug conjugate therapy in breast cancer patients.",

keywords = "Enzyme immunoassay, Human breast cancer cell lines, JAA-F11 monoclonal antibody, Monoclonal antibody, Thomsen-Friedenreich antigen",

author = "Kimiko Ferguson and Arti Yadav and Susan Morey and Julia Abdullah and Gabriel Hrysenko and Eng, \{Jing Ying\} and Munawwar Sajjad and Stephen Koury and Kate Rittenhouse-Olson",

year = "2014",

month = feb,

doi = "10.2217/fon.13.209",

language = "English",

volume = "10",

pages = "385--399",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer

AU - Ferguson, Kimiko

AU - Yadav, Arti

AU - Morey, Susan

AU - Abdullah, Julia

AU - Hrysenko, Gabriel

AU - Eng, Jing Ying

AU - Sajjad, Munawwar

AU - Koury, Stephen

AU - Rittenhouse-Olson, Kate

PY - 2014/2

Y1 - 2014/2

N2 - Aim: The Thomsen-Friedenreich antigen (TF-Ag) is a disaccharide hidden on normal cells, but selectively exposed on the surface of breast, colon, prostate and bladder cancer cells. JAA-F11, a highly specific monoclonal antibody to TF-Ag, reduces metastasis and prolongs survival in a mouse model. In addition, 124I-JAA-F11 localizes 4T1 tumors in mice. These studies continue translation of JAA-F11 to human breast cancer. Materials & methods & results: Of the 41 human breast cancer cell lines tested, 78% were positive for reactivity with JAA-F11 by whole-cell enzyme immunoassay and positivity occurred unrelated to estrogen, progesterone or HER2 receptor status. JAA-F11 inhibited the growth rate of the human cancer cell lines tested. At 1 h, approximately 80% of JAA-F11 internalized in the three cell lines tested. 124I-JAA-F11 specifically imaged human triple-negative tumors in mice by microPET. Conclusion: The results highlight the potential that humanized JAA-F11 may have for immunotherapy and drug conjugate therapy in breast cancer patients.

AB - Aim: The Thomsen-Friedenreich antigen (TF-Ag) is a disaccharide hidden on normal cells, but selectively exposed on the surface of breast, colon, prostate and bladder cancer cells. JAA-F11, a highly specific monoclonal antibody to TF-Ag, reduces metastasis and prolongs survival in a mouse model. In addition, 124I-JAA-F11 localizes 4T1 tumors in mice. These studies continue translation of JAA-F11 to human breast cancer. Materials & methods & results: Of the 41 human breast cancer cell lines tested, 78% were positive for reactivity with JAA-F11 by whole-cell enzyme immunoassay and positivity occurred unrelated to estrogen, progesterone or HER2 receptor status. JAA-F11 inhibited the growth rate of the human cancer cell lines tested. At 1 h, approximately 80% of JAA-F11 internalized in the three cell lines tested. 124I-JAA-F11 specifically imaged human triple-negative tumors in mice by microPET. Conclusion: The results highlight the potential that humanized JAA-F11 may have for immunotherapy and drug conjugate therapy in breast cancer patients.

KW - Enzyme immunoassay

KW - Human breast cancer cell lines

KW - JAA-F11 monoclonal antibody

KW - Monoclonal antibody

KW - Thomsen-Friedenreich antigen

UR - https://www.scopus.com/pages/publications/84896850864

U2 - 10.2217/fon.13.209

DO - 10.2217/fon.13.209

M3 - Article

C2 - 24559446

AN - SCOPUS:84896850864

SN - 1479-6694

VL - 10

SP - 385

EP - 399

JO - Future Oncology

JF - Future Oncology

IS - 3

ER -

Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this